Compliance for NKP Pharma with FactoryTalk® Optix™

NKP Pharma, a mid-market pharmaceutical manufacturer, faced a dual compliance and business challenge. Operating under FDA 21 CFR Part 11—the regulation governing electronic records and electronic signatures in pharmaceutical production—the company needed validated audit trails, access controls, and data integrity safeguards across its batch processes. Their existing IPC-SCADA infrastructure carried significant licensing and maintenance overhead, making cost-effective compliance difficult to sustain. Compounding the pressure, NKP Pharma's customers increasingly demanded direct access to production and batch data for their own quality assurance workflows. Without a modern visualization layer, the company risked both regulatory exposure and competitive disadvantage as contract pharmaceutical manufacturing became more data-transparency-driven.

NKP Pharma implemented FactoryTalk® Optix™, Rockwell Automation's modern HMI/SCADA platform, as a replacement for their legacy IPC-SCADA systems. FactoryTalk Optix was selected for its native support of 21 CFR Part 11 requirements—including electronic signatures, audit trail management, and role-based access controls—eliminating the need for costly third-party compliance add-ons. The platform's web-based architecture enabled NKP Pharma to extend data visibility directly to its pharmaceutical customers, giving them secure, role-appropriate access to batch records and process data. Rockwell Automation's solution also provided enhanced visualization dashboards and integrated batch data management, allowing production teams and quality personnel to monitor and review process parameters within a single, validated environment.

Deploying FactoryTalk Optix delivered measurable improvements across cost, compliance, and customer relationships. NKP Pharma achieved lower total cost of ownership compared to their prior IPC-SCADA setup, reducing both licensing overhead and the manual effort associated with maintaining compliance documentation. Key outcomes include:

• Improved 21 CFR Part 11 compliance for NKP Pharma's internal operations and extended to its customers
• Enhanced batch data management and visualization, streamlining quality review workflows
• Higher customer satisfaction through direct, secure data access—a differentiator in contract pharma
• Expanded market presence, with NKP Pharma positioning the platform as a foundation for future automated injectable pharmaceutical machinery

• Replacing legacy SCADA with a platform purpose-built for pharmaceutical compliance can reduce both cost and regulatory risk simultaneously.
• Extending data access to customers is increasingly a competitive requirement in contract manufacturing—choose platforms that support role-based external access.
• 21 CFR Part 11 features should be native to the platform, not bolted on; third-party compliance layers add cost and validation burden.
• Mid-market pharmaceutical manufacturers should evaluate modern HMI/SCADA not just for current needs but as a scalable foundation for expanding into higher-complexity product lines such as injectables.